Skip to main content
Clinical Trials/NCT04758364
NCT04758364
Completed
Not Applicable

Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy

GULIN FINDIKOGLU1 site in 1 country71 target enrollmentFebruary 20, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gait Disorder, Sensorimotor
Sponsor
GULIN FINDIKOGLU
Enrollment
71
Locations
1
Primary Endpoint
gait speed
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study planned to investigate the role of potential explanatory factors effecting the speed of gait such as muscle mass, aerobic capacity, physical activity status, cognitive function, blood pressure, and metabolic measures considering age, sex, and education years in diabetic individuals without neuropathy.

Detailed Description

Type 2 diabetic people will be screened by clinical symptoms of neuropathy and DN4 questionnaire. Among those who did not have neuropathic symptoms or who have DN4 score below 4 will be considered for the study.Then aerobic capacity will be measured by a cycle ergometer and VO2max will be obtained. Weight, body mass index and muscle mass will be measured by bioimpedance analysis. Physical activity status will be determined by International Physical Activity Score (IPAQ). Cognitive function will be evaluated by Mini Mental test. HbA1c and fasting blood glucose will be measured in venous blood after overnight fasting. Blood pressure will be measured in the sitting position after resting from the left arm. Speed of gait will be measured by an accelerometer.Then, the effect of above mentioned factors on speed of gait will be studied.

Registry
clinicaltrials.gov
Start Date
February 20, 2021
End Date
March 30, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
GULIN FINDIKOGLU
Responsible Party
Sponsor Investigator
Principal Investigator

GULIN FINDIKOGLU

Assoc Proffessor, MD, PhD

Pamukkale University

Eligibility Criteria

Inclusion Criteria

  • Individuals with Diabetes Mellitus less than 10 years but longer than 1 year
  • Absence of neuropathic symptoms
  • DN4 questionnaire sore less than 4

Exclusion Criteria

  • Individuals who had
  • insulin therapy,
  • poor glycemic control,
  • manifesting cardiovascular disease,
  • retinopathy or other visual problems,
  • diabetic neuropathy,
  • nephropathy,
  • cerebrovascular disease,
  • cognitive impairment,
  • heart failure,

Outcomes

Primary Outcomes

gait speed

Time Frame: The gait speed will be measured once within a month after the participants enrolled.

gait speed measured by wearable accelerometer

Study Sites (1)

Loading locations...

Similar Trials